Performance_NN of_IN Two_NP Commercial_NP Glycoprotein_NP G-Based_NP Enzyme_NP Immunoassays_NP for_IN Detecting_NP Antibodies_NNS to_TO Herpes_NP Simplex_NP Viruses_NP 1_CD and_CC 2_CD in_IN Children_NP and_CC Young_NP Adolescents_NP In_IN 61_CD patients_NNS 1_CD to_TO 14_CD years_NNS of_IN age_NN ,_, the_DT Gull/Meridian_NP enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) had_VBD a_DT sensitivity_NN of_IN 100_CD %_NN for_IN herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) and_CC specificities_NNS of_IN 74_CD %_NN for_IN HSV-1_NP and_CC 48_CD %_NN for_IN HSV-2_NP ._SENT In_IN 128_CD similarly_RB aged_VBN patients_NNS ,_, the_DT HerpeSelect_NP ELISA_NP (_( Focus_NP Technologies_NP )_) showed_VBD sensitivities_NNS of_IN 80_CD %_NN for_IN HSV-1_NP and_CC 88_CD %_NN for_IN HSV-2_NP ,_, and_CC specificities_NNS of_IN 97_CD %_NN for_IN HSV-1_NP and_CC 100_CD %_NN for_IN HSV-2_NP ._SENT Herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) infection_NN is_VBZ common_JJ in_IN childhood_NN and_CC may_MD be_VB indistinguishable_JJ from_IN viral_JJ or_CC bacterial_JJ stomatitis_NN ,_, otitis_NN media_NNS ,_, and_CC upper_JJ respiratory_JJ tract_NN infections_NNS (_( ,_, ,_, 14_CD )_) ._SENT HSV-2_JJ infections_NNS are_VBP unusual_JJ after_IN the_DT neonatal_JJ period_NN and_CC before_IN sexual_JJ debut_NN ;_: seroprevalence_NN begins_VBZ to_TO rise_VB in_IN late_JJ adolescence_NN ._SENT Virologic_JJ methods_NNS for_IN diagnosing_VBG HSV_NP infection_NN in_IN children_NNS are_VBP limited_VBN by_IN the_DT need_NN to_TO collect_VB samples_NNS early_JJ in_IN the_DT clinical_JJ course_NN and_CC by_IN the_DT need_NN to_TO perform_VB the_DT vigorous_JJ swabbing_VBG that_DT is_VBZ necessary_JJ to_TO obtain_VB infected_JJ cells_NNS from_IN mucosal_JJ surfaces_NNS or_CC from_IN lesions_NNS ._SENT Serologic_JJ tests_NNS to_TO detect_VB HSV_NP antibodies_NNS are_VBP available_JJ commercially_RB ._SENT Some_DT tests_NNS can_MD distinguish_VB HSV-1_NP from_IN HSV-2_NP antibodies_NNS on_IN the_DT basis_NN of_IN type-specific_JJ antigens_NNS of_IN glycoprotein_NN G-1_NP (_( gG-1_JJ )_) and_CC gG-2_NN ,_, respectively_RB ._SENT The_DT first_JJ such_JJ test_NN to_TO be_VB approved_VBN by_IN the_DT Food_NP and_CC Drug_NP Administration_NP was_VBD an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) from_IN Gull_NP Laboratories_NPS ,_, Salt_NP Lake_NP City_NP ,_, Utah_NP that_WDT was_VBD sold_VBN under_IN the_DT Premier_NP brand_NN by_IN Meridian_NP Diagnostics_NP (_( Cincinnati_NP ,_, Ohio_NP )_) (_( termed_VBD the_DT Gull/Meridian_NP ELISA_NP )_) ._SENT This_DT ELISA_NP was_VBD both_DT sensitive_JJ and_CC specific_JJ in_IN a_DT premarket_NN evaluation_NN of_IN adult_NN sera_NN ._SENT To_TO assess_VB the_DT accuracy_NN of_IN the_DT Gull/Meridian_NP ELISAs_NP for_IN children_NNS and_CC adolescents_NNS ,_, we_PP tested_VBD blood_NN samples_NNS from_IN healthy_JJ children_NNS from_IN southern_JJ Texas_NP (_( n_NN =_SYM 61_CD ;_: mean_JJ age_NN ,_, 7.4_CD years_NNS ;_: range_NN ,_, 1_CD to_TO 13_CD years_NNS )_) with_IN kits_NNS purchased_VBN from_IN Gull_NP Laboratories_NPS and_CC compared_VBD these_DT results_NNS to_TO those_DT obtained_VBN by_IN Western_NP blotting_VBG (_( WB_NP )_) ,_, a_DT well-validated_JJ "_`` gold_JJ standard_NN "_'' ._SENT Later_RBR ,_, when_WRB the_DT Gull/Meridian_NP ELISAs_NP were_VBD withdrawn_VBN from_IN the_DT market_NN ,_, we_PP extended_VBD this_DT study_NN to_TO evaluate_VB the_DT HerpeSelect_NP HSV-1_NP and_CC HSV-2_NP ELISAs_NP from_IN Focus_NP Technologies_NPS (_( formerly_RB MRL_NP )_) on_IN pediatric_JJ sera_NN (_( n_NN =_SYM 128_CD ;_: mean_JJ age_NN ,_, 5.7_CD years_NNS ;_: range_NN ,_, 1_CD to_TO 13_CD years_NNS )_) that_WDT had_VBD been_VBN sent_VBN to_TO the_DT University_NP of_IN Washington_NP Virology_NP Laboratory_NP for_IN HSV_NP type-specific_JJ serology_NN ._SENT Our_PP$ comparison_NN studies_NNS revealed_VBD substantial_JJ differences_NNS among_IN the_DT performances_NNS of_IN these_DT ELISAs_NP ._SENT The_DT seroprevalence_NN of_IN HSV-1_NP determined_VBN by_IN WB_NP in_IN Texas-based_JJ patients_NNS was_VBD 49_CD %_NN (_( 30_CD of_IN 61_CD positive_NN )_) ;_: no_DT patient_NN was_VBD positive_JJ for_IN HSV-2_NP ._SENT Of_IN the_DT sera_NN from_IN Seattle_NP ,_, 46_CD of_IN 128_CD (_( 36_CD %_NN )_) were_VBD seropositive_JJ for_IN HSV-1_NP by_IN WB_NP and_CC 8_CD of_IN 125_CD (_( 6_CD %_NN ;_: ages_NNS 11_CD days_NNS to_TO 14_CD years_NNS )_) were_VBD positive_JJ for_IN HSV-2_NP ._SENT All_DT eight_CD samples_NNS with_IN discordant_JJ results_NNS for_IN HSV-1_NP by_IN the_DT Gull/Meridian_NP ELISA_NP and_CC WB_NP were_VBD false_RB positive_JJ by_IN the_DT ELISA_NP ._SENT The_DT sensitivity_NN for_IN the_DT HSV-1_NP Gull/Meridian_NP ELISA_NP was_VBD 100_CD %_NN ,_, with_IN a_DT negative_JJ predictive_JJ value_NN (_( NPV_NP )_) of_IN 100_CD %_NN ._SENT The_DT specificity_NN for_IN HSV-1_NP was_VBD 74_CD %_NN ,_, with_IN a_DT positive_JJ predictive_JJ value_NN (_( PPV_NP )_) of_IN 79_CD %_NN ._SENT The_DT sensitivity_NN of_IN the_DT Gull/Meridian_NP HSV-2_NP ELISA_NP could_MD not_RB be_VB evaluated_VBN (_( none_NN were_VBD HSV-2_NP WB_NP positive_NN )_) ._SENT Thirty-two_NP of_IN 61_CD samples_NNS (_( 52_CD %_NN )_) were_VBD positive_JJ by_IN the_DT Gull/Meridian_NP HSV-2_NP ELISA_NP ,_, giving_VBG a_DT specificity_NN of_IN 48_CD %_NN and_CC a_DT PPV_NP of_IN 0_CD %_NN ._SENT TABLE_NN 1_CD |_SYM Results_NNS of_IN WB_NP and_CC two_CD ELISA_NP for_IN HSV-1_NP and_CC HSV-2_NP antibodies_NNS in_IN patients_NNS aged_VBN 1_CD to_TO 14_CD years_NNS from_IN Texas_NP and_CC Washington_NP The_DT results_NNS for_IN 5_CD of_IN 128_CD pediatric_JJ sera_NN tested_VBN by_IN the_DT HerpeSelect_NP HSV-1_NP ELISA_NP were_VBD equivocal_JJ ,_, and_CC the_DT sera_NN could_MD not_RB be_VB classified_VBN as_IN negative_JJ or_CC positive_JJ for_IN comparison_NN ._SENT For_IN the_DT remaining_VBG 123_CD sera_NN ,_, the_DT HerpeSelect_NP HSV-1_NP ELISA_NP had_VBD a_DT sensitivity_NN of_IN 80_CD %_NN and_CC a_DT specificity_NN of_IN 97_CD %_NN ,_, with_IN a_DT PPV_NP and_CC an_DT NPV_NP of_IN 95_CD and_CC 89_CD %_NN ,_, respectively_RB ._SENT Two_CD sera_NN had_VBD equivocal_JJ results_NNS with_IN the_DT HerpeSelect_NP HSV-2_NP ELISA_NP ._SENT Neither_DT was_VBD positive_JJ by_IN WB_NP for_IN HSV-2_NP ;_: one_CD was_VBD positive_JJ for_IN HSV-1_JJ antibody_NN by_IN both_DT WB_NP and_CC the_DT HerpeSelect_NP HSV-1_NP ELISA_NP ._SENT In_IN addition_NN ,_, three_CD sera_NN had_VBD atypical_JJ HSV-2_JJ results_NNS by_IN WB_NP and_CC could_MD not_RB be_VB scored_VBN by_IN that_DT test_NN as_IN either_DT negative_JJ or_CC positive_JJ ._SENT Of_IN the_DT 123_CD evaluable_JJ result_NN sets_NNS for_IN HSV-2_NP antibody_NN ,_, HerpeSelect_NP HSV-2_NP ELISA_NP had_VBD a_DT sensitivity_NN of_IN 88_CD %_NN ,_, a_DT specificity_NN of_IN 100_CD %_NN ,_, a_DT PPV_NP of_IN 100_CD %_NN ,_, and_CC an_DT NPV_NP of_IN 99_CD %_NN ._SENT Thus_RB ,_, two_CD commercial_JJ ELISAs_NP had_VBD very_RB different_JJ performance_NN characteristics_NNS with_IN pediatric_JJ sera_NN ._SENT The_DT Gull/Meridian_NP ELISA_NP (_( based_VBN on_IN immunoaffinity-purified_JJ gG-1_NN and_CC gG-2_NN )_) suffered_VBD from_IN very_RB low_JJ specificity_NN and_CC unacceptably_RB low_JJ PPVs_NNS ,_, especially_RB for_IN HSV-2_NP ._SENT At_IN least_JJS one_CD widely_RB used_VBN reference_NN test_NN ,_, the_DT gG-1_JJ and_CC gG-2_JJ immunodot_NN enzyme_NN assay_NN ,_, is_VBZ based_VBN on_IN antigens_NNS similar_JJ to_TO those_DT in_IN the_DT Gull/Meridian_NP ELISAs_NP ._SENT The_DT HerpeSelect_NP ELISAs_NP had_VBD high_JJ specificity_NN for_IN both_DT HSV-1_NP and_CC HSV-2_NP but_CC surprisingly_RB low_JJ sensitivity_NN for_IN HSV-1_NP (_( 80_CD %_NN )_) ._SENT Our_PP$ study_NN raises_VBZ important_JJ issues_NNS about_IN the_DT use_NN of_IN these_DT gG-based_JJ HSV_NP type-specific_JJ serologic_JJ tests_NNS in_IN children_NNS ._SENT The_DT very_RB low_JJ specificities_NNS of_IN the_DT Gull/Meridian_NP ELISAs_NP were_VBD surprising_JJ in_IN light_NN of_IN previous_JJ data_NNS for_IN adults_NNS ._SENT Although_IN these_DT tests_NNS could_MD be_VB more_RBR sensitive_JJ than_IN WB_NP ,_, this_DT higher_JJR sensitivity_NN (_( if_IN true_JJ )_) appears_VBZ to_TO apply_VB only_RB to_TO children_NNS ._SENT Alternatively_RB ,_, some_DT young_JJ people_NNS may_MD have_VB circulating_VBG factors_NNS that_WDT nonspecifically_RB bind_VBP glycoprotein_NN G_NN in_IN this_DT particular_JJ ELISA_NP ._SENT A_DT previous_JJ report_NN may_MD have_VB given_VBN an_DT early_JJ ,_, unrecognized_JJ warning_NN of_IN a_DT unique_JJ problem_NN with_IN Gull/Meridian_NP ELISAs_NP for_IN pediatric_JJ sera_NN ._SENT It_PP is_VBZ unclear_JJ whether_IN the_DT specificity_NN problem_NN with_IN Gull/Meridian_NP ELISAs_NP for_IN pediatric_JJ sera_NN is_VBZ restricted_VBN to_TO the_DT Gull_NP antigen_NN ._SENT Studies_NNS using_VBG immunoaffinity-purified_JJ HSV-2_JJ antigens_NNS in_IN gG-2-based_JJ tests_NNS other_JJ than_IN the_DT Gull/Meridian_NP ELISA_NP suggest_VBP a_DT reasonably_RB low_JJ HSV-2_NP prevalence_NN rate_NN in_IN children_NNS ;_: these_DT studies_NNS give_VBP no_DT insight_NN into_IN ELISA_NP performance_NN for_IN antibodies_NNS to_TO HSV-1_NP in_IN pediatric_JJ sera_NN ._SENT The_DT HerpeSelect_NP HSV-1_NP and_CC HSV-2_NP ELISAs_NP are_VBP based_VBN on_IN baculovirus_NN recombinant_JJ gG-1_NN and_CC gG-2_NN ._SENT Unlike_IN the_DT Gull/Meridian_NP ELISAs_NP ,_, these_DT tests_NNS with_IN pediatric_JJ sera_NN gave_VBD no_DT indication_NN of_IN excessive_JJ false-positive_JJ HSV-1_JJ results_NNS (_( two_CD of_IN 77_CD sera_NN )_) or_CC HSV-2_NP results_NNS (_( 0_CD of_IN 116_CD sera_NN )_) ._SENT However_RB ,_, the_DT sensitivity_NN for_IN HSV-1_NP was_VBD only_RB 80_CD %_NN ._SENT Two_CD of_IN nine_CD false-negative_JJ sera_NN were_VBD from_IN infants_NNS under_IN 1_CD year_NN of_IN age_NN and_CC could_MD have_VB represented_VBN low-titer_NN maternal_JJ antibodies_NNS ._SENT The_DT other_JJ seven_CD sera_NN were_VBD from_IN children_NNS with_IN a_DT median_JJ age_NN of_IN 4.5_CD years_NNS (_( range_NN ,_, 3_CD to_TO 12_CD )_) who_WP might_MD have_VB been_VBN in_IN the_DT process_NN of_IN seroconverting_NN ,_, based_VBN on_IN the_DT appearance_NN of_IN the_DT WB_NP profiles_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT accuracy_NN of_IN HSV_NP serologic_JJ testing_NN for_IN children_NNS appears_VBZ questionable_JJ with_IN current_JJ ELISAs_NP ._SENT False-positive_JJ HSV-1_JJ results_NNS may_MD lead_VB to_TO inappropriate_JJ treatment_NN or_CC to_TO unnecessary_JJ antiviral_JJ prophylaxis_NN in_IN immunosuppressed_JJ patients_NNS ._SENT Positive_JJ HSV-2_JJ tests_NNS for_IN children_NNS suggest_VBP the_DT occurrence_NN of_IN sexual_JJ abuse_NN ._SENT Our_PP$ limited_JJ testing_NN of_IN the_DT HerpeSelect_NP ELISAs_NP provides_VBZ cautious_JJ optimism_NN that_IN these_DT tests_NNS are_VBP reasonably_RB accurate_JJ for_IN children_NNS ._SENT However_RB ,_, prospective_JJ studies_NNS using_VBG virologic_JJ diagnosis_NN of_IN infection_NN as_IN the_DT gold_JJ standard_NN are_VBP needed_VBN ._SENT A_DT serologic_JJ diagnosis_NN of_IN HSV_NP infection_NN in_IN children_NNS should_MD be_VB made_VBN with_IN caution_NN ._SENT A_DT negative_JJ test_NN should_MD be_VB followed_VBN by_IN testing_NN in_IN 6_CD to_TO 8_CD weeks_NNS to_TO detect_VB seroconversion_NN ._SENT Positive_JJ results_NNS for_IN HSV-2_JJ antibodies_NNS should_MD be_VB confirmed_VBN by_IN a_DT second_JJ type-specific_JJ test_NN ,_, such_JJ as_IN WB_NP or_CC the_DT Focus_NP HerpeSelect_NN immunoblot_NN ._SENT 